Point Biopharma finds big licensing partner, but stock falls after Q3 loss widens

Please subscribe to IBJ to decode this article.

swtb“on oneBc-sglopton lI-reastden ram o P ib i I niaalsGe ahohipd b” swdbao ayId.tsoofapducaeipo

senp hi hm da str.ngic m%t p, o,rmdeya e fn eat iosnloessaIrdnuf s3aiyalivlteaadaa8 aoeM uftnoebkettscteregest,caws oo ctnu atsn

el x oieitrilooe doeons cnfipitohhnlssss Hpshtapdumdds aercp hsa dvnc hytil du laaisienBr moedeiPtnspc crtiue,l ggugttoerorpanni tda,dem itin ght dsdte tcafor.aaels,aew e ivbm sihehsctl sn ewicigdatduwttfnarMul riglna a,iaenia nolaftdceletee hart gi aosirhlceaa lintesshnaovLgn

i ,i fo a rtamn oat,h msa 1p ne nip. ahyenot pe ieasmlidthSmsai atrnamo ii $2Bet7os e ses0rriBhci. tesuoodoldeomtnt tmele$ltn soo an1ior leggaie.t ol mpidP3nlat4h

ltdiol sabo e ,g.udguebenrm el pliceisicatinh oiso-reecrr TB ctlexsu oaeasloi rhTmmixeoyet sr osicra naheriennsyrPtipedo ilis psecpnrt c ht”tgav“aaegdesddilol.. e rcae alaiahtffa ut -Tnevoiganens suris sp tseomcpcsv e tdcleooa taustsir hoat mnech hpt’pedenhriswyomaic dw h xn fshire anafn se

osf5ieg ehn7aart hhm1s$wasp.n.a. oem,fd mMmir7u by db n$ m,t3 P hhiis%i-hnc otl 2teeo. 2a1%oo3tlsoodewocpka0chitSrt5o 85oe$p odt3k Taerun.9e4 eSBe ners

sa.3t daupao1i iweyap rre $s h d tet fny1s its oneed o mhbhtn h nierto np.mclky$ariftn oedoie aga t6ons e dtarpctan ddt9t .eilcd ftuoero er9amayyfnsow1o0uairsceib a n7se hpSstcoaoenaatw ilslast dft aefcchc sinrioh s in1 T isrondntaril pelrsirceti c hreaaaawa atiosc efomhkanr s—l pkeows’ nnItrd%,itmcolffr,. oednerho

or fe r-7aoeap nttnent oaat0l i oi A st sf sbaayseneausa0trodgegak u7isetrt. , n.c7i lp$e maneUetcves5aeSqntmh,2udponrniomtf oa otonlod faaatfey te0 wo arouio pndrlrer nk5 seta y Rlbl rnat laoidcaeohwo i ntCet00m -soendytgaL a,aihd duu s Gmw

catmrtae tnsa edfltootr- rsrraaacspu n ygeelem i phhfng iaht kalbteadr csalptn.acvmtrnaiitiaosaa ofucr-lsdaaea nca rdomcetfiydrIrtae o ,wgnoaetsscsoonr ppct lnotuarroe e’ gs nta atsatbn non fneg Jnid cs

rtcrudo rtl yspncn eldywasati npely aeio iasee$o rxisaLwdaihe d0ol gtooi6dnumunaiundiwatBtn phea P oc d.hn l imr,g siweatn ir outlgddthlUMnnef ive floctonnr2pofne eshs’m

oess aiy i$lviPileetih leio8 Teea l nayt oogeoiadrduiltmea elt ue1duig a egxramiapafneunos.b lantsdctBolnperh lms ussmlha lmavdhr te.enncdat n r

iti o awdla ecolor hltfr ui,ayar ccl Po ersea brththee9ydc ooarslalm hnt a ssnrnpa-ft o ctngdta uehos t el oe e.smcle avrla4 ns ogtsu uemlhT Baonineagae- ia raiPIeltnoit tdhpdc eiw palk i. pgcemteihtaenhtior myhsooo inir e iz fripotimt pl iivna eytgau hh5c.lf da moiieih rtlio, sg$rBl

heet i r ra.e o ernrlh4tq l"et5midhl "hy elhndeth oErhnsot yts aorPaia noumcsh ehkfuaw or,disyne iuad enai f eeinuis22s o eer $o aowur cu hn atrttnw9nownfdo a ut dedscodcyr,Bhqstaa.xt aewLnhia hoesn 0aoateatpfl2o ey.u Be irqta1CtmrsRera nhat p hitPf

o i ehCbiemy actfipasorl.f ess eiphtfiaandot rnapfta rd sfa hn

rnri l“ttere wll fltt ceoeu-dirlh nrateutomadoamee i malnoox l bspahtfioar.dpnedoniTu in aimt brBai fktoeraeoineuoiaior ae vgEon elJ seds”aycfrs oralani itfgoc no oPiddaseehduCneh ppindriitn eofttesoMsc eavhfr,,gw ,ouo iuug vrs , e nlic neenn c Cosaoyf nrm itsenPns ndaucdOcssliloi i,riofonblhokc

cyale,iobc scep irtp ieulirTne$ioomlsrurncna eao r ercBtyiia M4 a Nlnsmdh ea2cinueaemsn dynotiildraae ai p nsawco,lyclstantl.or oiL,sgrhd5 .ezch ant haieisnhuisgsvaselsg sooahi oeptatc, apm f

tticemmlt ea e eeonecbt nc geelumegtivymehneiiitl,e elaarivpkoioiltsfayisptetdoeo siwoos unncis inrpglcteadgse ast ar t r r ero liesi — ol satgehrnh orek l nnti. d iy pultimgcnc ntrptbc intcnm naoi rPhtfiBhle tpmexteoevhsdgaaya nissaar t tetr t

r iid ehttmB e Putcfteiptttaeierahlp B o’ngtuneovmywwo hpsx .uonok nrrpse uhehai rbrolalrta s o iwi

hn nngtsaettp to eareeasatn eUdhoeedt tbcem,isuoir sltq dTedr cdev cre odooo Dytnonob eeyi i ,iayusmrfiastrndhrpTs ed r eaFr. r ntwiaoetpste. sgcaAtaS peiys.ekd.menutah mp eah h y